TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma

Inclusion Criteria: 1. Age: 18-75 years; 2. Diagnosed as HCC based on the American Association for the Study of Liver Diseases 2018 Guideline on Liver Cancer Diagnosis; 3. Initial tumor recurrence following curative surgical resection (R0 hepatectomy) (two to three lesions with at least one lesion \>3 cm in diameter or more than three lesions of any diameter). Tumor burden ≤ 50% and no distant metastasis and macroscopic vascular invasion; 4. Histologically confirmed microvascular invasion in the specimen slices of surgically removed primary tumor; 5. Eastern Cooperative Oncology Group scoring 0-1; 6. Child-Pugh A class; 7. At least 3 months of life expectancy; 8. Adequate hematologic, hepatic and renal function: absolute neutrophil count ≥ 1.5x10\^9/L, platelet ≥ 60 x10\^9/L, Hb ≥ 90g/L, albumin ≥ 30g/L, total bilirubin ≤ 1.5 x upper limit of normal (ULN) , ALT \< 5×ULN, AST \< 5×ULN, alkaline phosphatase \< 4×ULN, extended prothrombin time not exceeding 6s of ULN, creatine\<1.5×ULN. Exclusion Criteria: 1. Have lesions which are diffuse or can not be evaluated via imaging. Tumor burden\>50%; 2. Have a history of hepatic encephalopathy, refractory ascites, severe esophageal and gastric varices or variceal bleeding and obstructive jaundice; 3. Have contraindications for TACE; 4. Have metastasis in central nervous system; 5. Allergic to intravenous contrast agents; 6. Pregnant or breastfeeding women, or expecting to conceive or father children within two years; 7. Infection of HIV, known syphilis requiring treatment; 8. Have a known history of prior invasive malignancies within 5 years before enrolment; 9. Patients with allotransplantation; 10. Severe dysfunction involving heart, kidney or other organs; 11. Severe active clinical infection which is over grade 2 based on NCI-CTC version 4; 12. Patients with mental disorders which may impact informed consent; 13. Unable to orally take drugs; 14. Participating other clinical drug trials 12 months before enrolment.